Aurobindo Pharma surpasses Q4 expectations with strong sales and EBITDA growth, optimistic outlook ahead.

From Investing.com: 2024-05-27 23:04:04

Aurobindo Pharma beats expectations in Q4 FY24 with 17% sales and 68% EBITDA growth, surpassing Goldman Sachs’ forecast. Strong performance attributed to key market growth and higher EBITDA margin of 22.3%. Optimistic outlook for FY25 includes US market momentum and PLI project on track for peak utilization by September.

Goldman Sachs raises Aurobindo Pharma’s 12-month SOTP target price to INR 1,325 with 11% upside potential. Maintains Buy rating due to current valuation discount and positive business outlook. Europe revenues up 8% YoY, aiming for consistent growth in FY25 and margin improvement to 20% in medium term.

InvestingPro offers insights into Aurobindo Pharma, valuing stock at INR 1,270 with strong potential. ProTips feature highlights stock’s history of dividends, low P/E ratio, and profitability, reinforcing attractiveness. Subscription to InvestingPro provides actionable insights for informed investment decisions, now at a 69% discount for a limited time.



Read more at Investing.com: Aurobindo Pharma Outperforms Expectations with Strong Q4, Eyes Robust Growth Ahead By Investing.com